Pavmed Inc (PAVM) Stock Price, Quote & News

Company Profile

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precance...

Industry: Medical Devices

Sector: Healthcare

Phone: 917 813 1828

Website: www.pavmed.com

Address:

360 Madison Avenue, 25th Floor, New York, United States

chuckjackson May. 31 at 4:17 PM

$PAVM $LUCD part of the reason I brought up the topic of whether draft LCDs occur in June is that I wanted to adjust my expectations on when to expect the draft. There were weeks when I have been very disappointed that the draft has not been received since my expectations were so high. With management now communicating "near future" instead of imminent, I have become uncertain on what to expect. We are at the 9 months point post-cac. Any sense of timeliness given a very positive meeting is also fading. Given what I've seen, my expectations are going to take a summer vacation. Imo, the next chance for a draft will be mid-July. I will still check each week for the 1% chance as my holdings are in pavm, and I believe that any spike will be short lived given the participation of Ayrton, the 4.61M shares of call-able warrants and the dillutive structure in place.

1 · Reply

chuckjackson May. 30 at 2:22 PM

$LUCD $PAVM @oaksapollo have you seen anything to indicate that June historically is a slow month (possibly because of vacations) and we will need to wait for July / August? According to Gemini, this is the draft lcd activity for summer 2025.

3 · Reply

dmc4321 May. 29 at 12:12 AM

$LUCD & $PAVM @RetiredMD @oaksapollo @PortfolioMgmt23 are all competing for the biggest WHOPPER of the week. They all tried hard but I have got to say that @RetiredMD wins it be a NOSE (🤥 🤥) If you had any brains this would scare you straight. The commercial success of EsOguard has always been about PCP's both ordering and as importantly DOING THE TESTS on site. Look at these ColoGuard stats from 2014 and compare to LUCD's 2000 tests a year which is the current run rate. During 2014, Exact Sciences generated an estimated roughly $1.5 million from Cologuard, the company said on January 12, citing preliminary data. Exact Sciences said it completed and reported diagnostic results for 4,024 Cologuard tests, while more than 4,000 physicians wrote at least one prescription for the test. The patient compliance rate was 74.6% as of December 31. In 2014 they had 4000 PCP's writing scripts. Today EsoGuard has MAYBE 200 PCP's writing scrips. Thats what you need to SCALE. PCP's.

1 · Reply

dmc4321 May. 28 at 5:41 PM

$LUCD $PAVM $MU This is on you for being weak and compliant. So dont bitch and moan. Its a you issue not a management issue. For 5 years Management has misled you YET you continue to believe and invest your after tax dollars into them because you "BELIEVE" what they say.🥴 All the information is in the public domain. Look at what they said or intimated would happen and count how many times it was accurate to timeline and outcome. ZERO. Not even close. ZERO. It is all in black and white yet you act shocked. You have been dumber than a rock so your choice is do I continue doing that or do I change and challenge the FALES NARRATIVE. Look at @Maineman5 he claims a 10X increase is feasible and instead of saying "that's bullshit" you say "I hope so" Act like a cuck you loose money like a cuck!" With nearly 250M shares outstanding 10X is $2.5B. Run rate today is $4M PER YEAR plus mass testing events so $10M tops. Loses $M50+ per year. Justify $2.25B valuation. IMPOSSIBLE. FACT

1 · Reply

chuckjackson May. 28 at 3:00 PM

$LUCD $PAVM the opportunity cost has been huge. We all could have invested in $MU for a few months and achieved the gains we dream of in lucd. I hope the wait is worth it

3 · Reply

BigJuicy May. 28 at 2:57 AM

$PAVM tonight or mid/late June… $LUCD

1 · Reply

dmc4321 May. 27 at 4:45 PM

$LUCD & $PAVM @PortfolioMgmt23Mg and @oaksapollo are fellow disciples of the PUMP. LUCD loses $50M+ per year and is broke AGAIN in January of 2027. Currently after a year of INTENSE FOCUS to increase the number of CMS qualified EsoGuard tests done according to Lishan the CEO and Dennis the CFO they are doing the SAME as before that INTENSE FOCUS. So 1000 CMS QUALIFIED tests in the 1st half of 2025, and 1000 CMS QUALIFIED tests in the 2nd half of 2025, and guess what LUCD did LESS than 500 CMS QUALIFIED tests in Q1 2026. To be fair the drop is expected as its the first Qtr and deuctible issues etc play a part. They KEY takeaway is that after a year of INTENSE FOCUS, NOTHING HAS CHANGED. NOTHING So surely you should model LUCD as capable of doing 500 tests a quarter which is $1M a Quarter or $4MA year, add in mass testing events for another $6M for $10M and you have cut your losses which MUST BE FUNDED to $42M a year. Does that make you happy?

1 · Reply

chuckjackson May. 27 at 3:18 PM

$PAVM I guess we get the good news tonight

0 · Reply

dmc4321 May. 27 at 4:18 AM

Wow No thanks for trying to help you by CORRECTING YOUR MISTAKE? Or does pointing out the FACT that TODAY $PAVM Is valued at 30% more than its 31m shares (NOT the 38M you claimed🤥) that it owns of $LUCD not what you want to hear as it kinda kills your PUMP? I used to work out of 60 Broad BTW.

1 · Reply

dmc4321 May. 26 at 10:13 PM

$LUCD & $PAVM Its an @oaksapollo post so its a LIE. Kyle Mikson: So I wanted to start where we typically start off with and ask about the percentage of claims that are represented by the Medicare segment. And when you think about some of your efforts to either increase the sales team in favor of more like Medicare-focused reps or maybe train them or incentivize them a little more to kind of increase that kind of area -- that segment of the market a bit more? How has that progress as well in light of the -- hopefully, like increased percentage like the mix as well? Lishan Aklog: I'll let Dennis touch on the numbers, and we can fill in some of the operational side as well. Dennis McGrath: So Kyle, the -- I'll call it the government group, which is predominantly Medicare and Medicare Advantage was 13% in the first quarter. As you recall, in the fourth quarter, it was around 15%. That 2% delta is around 60-some tests.

0 · Reply

PAVmed reports Q1 non-GAAP EPS ($1.17) vs. ($1.97) last year

May 15, 2026, 8:30 AM EDT - 16 days ago

PAVmed Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 16 days ago

PAVmed Quarterly report: Q1 2026

May 15, 2026, 8:30 AM EDT - 16 days ago

PAVmed Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 16 days ago

PAVmed Slides: Q1 2026

May 15, 2026, 8:00 AM EDT - 16 days ago

Market Cap	6.17M
Revenue (ttm)	70,000.00
Net Income (ttm)	400,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	571.43%
Debt to Equity Ratio	0.60

Volume	10,800
Avg Vol	13,568
Day's Range	N/A - N/A
Shares Out	996,000.00
Stochastic %K	31%
Beta	0.64
Analysts	Sell
Price Target	$16.00